At a glance
- Originator Medicines for Malaria Venture; The National Center for Genetic Engineering and Biotechnology
- Developer Institute of Tropical Medicine, Nagasaki University; Medicines for Malaria Venture; Sanaria; Washington University School of Medicine
- Class Antimalarials; Diaminopyrimidines; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Malaria(Prevention, In volunteers) in Belgium (PO, Capsule)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Malaria(In volunteers) in United Kingdom (PO, Capsule)